Literature DB >> 9514543

Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.

I Sakaida1, Y Matsumura, S Akiyama, K Hayashi, A Ishige, K Okita.   

Abstract

BACKGROUND/AIM: A herbal medicine, Sho-saiko-to (TJ-9), has recently been orally administered to patients with chronic liver disease in Japan and has been reported to inhibit the development of hepatocellular carcinoma. The aim of this study was to investigate whether TJ-9 has an inhibitory effect on the development of preneoplastic lesions and liver fibrosis in rats.
METHODS: The effects of the TJ-9 were examined using the choline-deficient L-amino acid-defined (CDAA) diet-induced liver fibrosis model in 16-week-old male Wistar rats.
RESULTS: TJ-9 (1% w/w) prevented fibrosis, as indicated by reduced hydroxyproline content in the liver and inhibition of the increase in a serum marker of fibrosis (hyaluronic acid), without reducing the increase in serum alanine aminotransferase and aspartate aminotransferase. TJ-9 also reduced the expression of type III procollagen alpha 1 mRNA in the liver, as well as the proliferation of myofibroblast-like cells (activated stellate cells, activated Ito cells). Furthermore, TJ-9 reduced the number of preneoplastic lesions, detected as enzyme-altered (glutathione S-transferase placental form-positive) lesions, in the liver.
CONCLUSIONS: These results indicate that the herbal medicine Sho-saiko-to (TJ-9) prevents fibrosis as well as preneoplastic lesions, not by inhibiting hepatocyte cell death but by inhibiting the activation of stellate cells, which are considered to be the main collagen-producing cells, leading to a reduction in the development of preneoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514543     DOI: 10.1016/0168-8278(88)80017-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  Semi-quantitative analysis of cytokine mRNA expression induced by the herbal medicine Sho-saiko-to (TJ-9) using a Gel Doc system.

Authors:  X X Huang; M Yamashiki; K Nakatani; T Nobori; A Mase
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  The Inhibition of Indoleamine 2,3-Dioxygenase Accelerates Early Liver Regeneration in Mice After Partial Hepatectomy.

Authors:  Hideyuki Ogiso; Hiroyasu Ito; Ayumu Kanbe; Tatsuya Ando; Akira Hara; Masahito Shimizu; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Dig Dis Sci       Date:  2017-06-21       Impact factor: 3.199

3.  Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats.

Authors:  I Sakaida; K Hironaka; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

4.  Current status of novel antifibrotic therapies in patients with chronic liver disease.

Authors:  Michal Cohen-Naftaly; Scott L Friedman
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

5.  Loss of inhibitory growth regulation by TGF-beta1 in preneoplastic lesions in rat liver.

Authors:  I Sakaida; K Hironaka; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

Review 6.  Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine.

Authors:  Yuewen Gong
Journal:  Chin J Integr Med       Date:  2012-03-30       Impact factor: 1.978

7.  Correlation between stellate cell activation and serum fibrosis markers in choline-deficient L-amino acid-defined diet-induced rat liver fibrosis.

Authors:  K Hironaka; I Sakaida; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 8.  Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.

Authors:  Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-01-07       Impact factor: 5.810

9.  PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.

Authors:  Yuqing Liu; Eric Lik Hang Lui; Scott L Friedman; Lei Li; Tao Ye; Yongjun Chen; Ronnie T Poon; Jana Wo; Tsz Wai Kok; Sheung Tat Fan
Journal:  Lab Invest       Date:  2008-12-29       Impact factor: 5.662

10.  Inhibitory effects of armepavine against hepatic fibrosis in rats.

Authors:  Ting-Chun Weng; Chien-Chang Shen; Yung-Tsung Chiu; Yun-Lian Lin; Cheng-Deng Kuo; Yi-Tsau Huang
Journal:  J Biomed Sci       Date:  2009-09-02       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.